Amit Narayan, MD
Hospitalist · New York, NYNPI 1053774141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$624
- Amgen$428
- GSK$337
- AbbVie$337
- Bayer$319
- Noven Therapeutics, LLC$298
- plus $1K from 27 others
Across 21 payments — averaging $2844.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$36K
- Exact Sciences$24K
What the payments were for
- Food & beverage$3,731100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $624 |
| Amgen | 18 | $428 |
| GSK | 15 | $337 |
| AbbVie | 22 | $337 |
| Bayer | 11 | $319 |
| Noven Therapeutics, LLC | 17 | $298 |
| AstraZeneca | 14 | $262 |
| Lilly USA, LLC | 12 | $229 |
| Esperion Therapeutics, Inc. | 10 | $193 |
| Exact Sciences | 7 | $124 |
| Novartis | 3 | $56 |
| Pfizer | 3 | $53 |
| Boston Scientific | 2 | $48 |
| Philips North America LLC | 2 | $42 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Saluda Medical Americas, Inc. | 1 | $30 |
| Linus Health, Inc. | 2 | $28 |
| Si-bone, Inc. | 1 | $27 |
| Baxter Healthcare | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Merck | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Echosens North America, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Nevro Corp. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,739 in reported general payments places this provider in the 95th percentile of 1,860 hospitalist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $84,601 |
| RybelsusSemaglutide | 33 | $59,775 |
| MounjaroTirzepatide | 51 | $57,510 |
| JardianceEmpagliflozin | 45 | $52,693 |
| OzempicSemaglutide | 40 | $49,763 |
| XareltoRivaroxaban | 59 | $48,963 |
| Repatha SureclickEvolocumab | 46 | $44,927 |
| FarxigaDapagliflozin Propanediol | 40 | $44,339 |
| JanuviaSitagliptin Phosphate | 44 | $44,298 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $33,278 |
| MyrbetriqMirabegron | 48 | $33,014 |
| JanumetSitagliptin Phos/Metformin Hcl | 42 | $26,552 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $18,951 |
| GemtesaVibegron | 29 | $18,642 |
| TrulicityDulaglutide | 14 | $16,797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $624 | $109,53873 claims |
| PfizerEliquis, Premarin | $53 | $88,61899 claims |
| Lilly USA, LLCMounjaro, Trulicity | $229 | $74,30865 claims |
| MerckJanuvia, Janumet | $18 | $70,85086 claims |
| Johnson & JohnsonXarelto | $18 | $48,96359 claims |
| AstraZenecaFarxiga | $262 | $44,33940 claims |
| GSKTrelegy Ellipta | $337 | $33,27834 claims |
| Esperion Therapeutics, Inc.Nexletol | $193 | $12,64611 claims |
| AbbVieSynthroid | $337 | $2,42031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,860 hospitalist providers in New York.
Other hospitalist in New York
- Yair SapersteinNew York$43K
- Timothy TiutanNew York$42K
- Natasha VartakNew York$35K
- Sunil BhattNew York$25K
- Domenico AcciliNew York$21K
- Peter TingNew York$17K
- Amihai RottenstreichNew York$16K
- Matthew McCarthyNew York$12K
- John ChelicoNew York$11K
- Richard LinNew York$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.